Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct 17;17(12):94.
doi: 10.1007/s11910-017-0802-6.

Microbiota-Brain-Gut Axis and Neurodegenerative Diseases

Affiliations
Review

Microbiota-Brain-Gut Axis and Neurodegenerative Diseases

Eamonn M M Quigley. Curr Neurol Neurosci Rep. .

Abstract

Purpose of review: The purposes of this review were as follows: first, to provide an overview of the gut microbiota and its interactions with the gut and the central nervous system (the microbiota-gut-brain axis) in health, second, to review the relevance of this axis to the pathogenesis of neurodegenerative diseases, such as Parkinson's disease, and, finally, to assess the potential for microbiota-targeted therapies.

Recent findings: Work on animal models has established the microbiota-gut-brain axis as a real phenomenon; to date, the evidence for its operation in man has been limited and has been confronted by considerable logistical challenges. Animal and translational models have incriminated a disturbed gut microbiota in a number of CNS disorders, including Parkinson's disease; data from human studies is scanty. While a theoretical basis can be developed for the use of microbiota-directed therapies in neurodegenerative disorders, support is yet to come from high-quality clinical trials. In theory, a role for the microbiota-gut-brain axis is highly plausible; clinical confirmation is awaited.

Keywords: Alzheimer’s disease; Antibiotics; Fecal microbiota transplantation; Gut-brain axis; Microbiome; Microbiota; Neurodegenerative diseases; Parkinson’s disease; Probiotics.

PubMed Disclaimer

References

    1. Science. 2011 Oct 7;334(6052):105-8 - PubMed
    1. J Physiol. 2009 Sep 1;587(Pt 17):4153-8 - PubMed
    1. J Neurovirol. 2016 Feb;22(1):22-32 - PubMed
    1. Eur J Pharmacol. 2017 Dec 15;817:86-95 - PubMed
    1. Sci Rep. 2016 Jul 21;6:30028 - PubMed

MeSH terms